Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Clinical Proteomics

Fig. 1

From: A novel workflow combining plaque imaging, plaque and plasma proteomics identifies biomarkers of human coronary atherosclerotic plaque disruption

Fig. 1

Establishing a library of protein that are present in coronary plaque debris, captured by the FilterWire device. a In order to identify proteins acutely released into circulation from a disrupted plaque, we first established a library of plaque proteins by untargeted proteomic analysis of plaque debris captured by a distal protection device with pore size of 110 μm. (FilterWire, Boston Scientific), positioned in the coronary artery downstream from the plaque during PCI. Concurrently, a second FilterWire was incubated at 37.5 °C ex vivo in heparinised blood from the same patient (obtained at the beginning of the procedure, before angioplasty), for the same duration as the PCI procedure. This separate FW served as a control sample for the one deployed in the coronary artery in the same patient, in order to identify the non-specific blood proteins which may adhere to the FW during the PCI process, other than plaque debris. b These paired samples were analysed using the proteomics workflow as described in the manuscript. 423 proteins were significantly enriched in FilterWire compared to FilterWire-Control and considered to be plaque specific proteins

Back to article page